Open Access

Vaccines

, volume 8 , issue 3 , pages 382

Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin

Sabari Nath Neerukonda ¹

Russell Vassell ¹

Carol Weiss ¹

Hide authors affiliations Show authors affiliations: 1 affiliation

Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA |

Publication type: Journal Article

Publication date: 2020-07-12

MDPI

Vaccines

scimago Q1

wos Q2

SJR: 1.024

CiteScore: 9.9

Impact factor: 3.4

ISSN: 2076393X

DOI: 10.3390/vaccines8030382

Copy DOI

PubMed ID: 32664628

Drug Discovery

Pharmacology

Infectious Diseases

Pharmacology (medical)

Immunology

Abstract

Influenza continues to be a public health threat despite the availability of annual vaccines. While vaccines are generally effective at inducing strain-specific immunity, they are sub-optimal or ineffective when drifted or novel pandemic strains arise due to sequence changes in the major surface glycoprotein hemagglutinin (HA). The discovery of a large number of antibodies targeting the highly conserved stem region of HAs that are capable of potently neutralizing a broad range of virus strains and subtypes suggests new ways to protect against influenza. The structural characterization of HA stem epitopes and broadly neutralizing antibody paratopes has enabled the design of novel proteins, mini-proteins, and peptides targeting the HA stem, thus providing a foundation for the design of new vaccines. In this narrative, we comprehensively review the current knowledge about stem-directed broadly neutralizing antibodies and the structural features contributing to virus neutralization.

Found

1 citation

Efremov Roman

DSc in Biological/biomedical sciences

247 publications, 7 301 citations, 7 reviews

h-index: 44

Research interests

Biophysics

Top-30

Journals

	1 2 3
Vaccines	Vaccines, 3, 7.5% Vaccines 3 publications, 7.5%
Viruses	Viruses, 3, 7.5% Viruses 3 publications, 7.5%
Antibodies	Antibodies, 2, 5% Antibodies 2 publications, 5%
npj Vaccines	npj Vaccines, 2, 5% npj Vaccines 2 publications, 5%
Proceedings of the National Academy of Sciences of the United States of America	Proceedings of the National Academy of Sciences of the United States of America, 2, 5% Proceedings of the National Academy of Sciences of the United States of America 2 publications, 5%
Nature Communications	Nature Communications, 2, 5% Nature Communications 2 publications, 5%
Veterinary Sciences	Veterinary Sciences, 1, 2.5% Veterinary Sciences 1 publication, 2.5%
Frontiers in Immunology	Frontiers in Immunology, 1, 2.5% Frontiers in Immunology 1 publication, 2.5%
Vaccine	Vaccine, 1, 2.5% Vaccine 1 publication, 2.5%
Molecular Therapy - Methods and Clinical Development	Molecular Therapy - Methods and Clinical Development, 1, 2.5% Molecular Therapy - Methods and Clinical Development 1 publication, 2.5%
Journal of Biological Chemistry	Journal of Biological Chemistry, 1, 2.5% Journal of Biological Chemistry 1 publication, 2.5%
Advanced NanoBiomed Research	Advanced NanoBiomed Research, 1, 2.5% Advanced NanoBiomed Research 1 publication, 2.5%
ACS Chemical Biology	ACS Chemical Biology, 1, 2.5% ACS Chemical Biology 1 publication, 2.5%
Molecular Biology	Molecular Biology, 1, 2.5% Molecular Biology 1 publication, 2.5%
Human Vaccines and Immunotherapeutics	Human Vaccines and Immunotherapeutics, 1, 2.5% Human Vaccines and Immunotherapeutics 1 publication, 2.5%
ACS Nano	ACS Nano, 1, 2.5% ACS Nano 1 publication, 2.5%
Science immunology	Science immunology, 1, 2.5% Science immunology 1 publication, 2.5%
International Journal of Pharmaceutics	International Journal of Pharmaceutics, 1, 2.5% International Journal of Pharmaceutics 1 publication, 2.5%
Virology	Virology, 1, 2.5% Virology 1 publication, 2.5%
Mendeleev Communications	Mendeleev Communications, 1, 2.5% Mendeleev Communications 1 publication, 2.5%
Journal of Medical Virology	Journal of Medical Virology, 1, 2.5% Journal of Medical Virology 1 publication, 2.5%
Science	Science, 1, 2.5% Science 1 publication, 2.5%
Science advances	Science advances, 1, 2.5% Science advances 1 publication, 2.5%
European Journal of Immunology	European Journal of Immunology, 1, 2.5% European Journal of Immunology 1 publication, 2.5%
Folia Microbiologica	Folia Microbiologica, 1, 2.5% Folia Microbiologica 1 publication, 2.5%
Biochimica et Biophysica Acta - Biomembranes	Biochimica et Biophysica Acta - Biomembranes, 1, 2.5% Biochimica et Biophysica Acta - Biomembranes 1 publication, 2.5%
	1 2 3

Publishers

	1 2 3 4 5 6 7 8 9
MDPI	MDPI, 9, 22.5% MDPI 9 publications, 22.5%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 6, 15% Cold Spring Harbor Laboratory 6 publications, 15%
Springer Nature	Springer Nature, 5, 12.5% Springer Nature 5 publications, 12.5%
Elsevier	Elsevier, 5, 12.5% Elsevier 5 publications, 12.5%
Wiley	Wiley, 3, 7.5% Wiley 3 publications, 7.5%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 3, 7.5% American Association for the Advancement of Science (AAAS) 3 publications, 7.5%
American Chemical Society (ACS)	American Chemical Society (ACS), 2, 5% American Chemical Society (ACS) 2 publications, 5%
Proceedings of the National Academy of Sciences (PNAS)	Proceedings of the National Academy of Sciences (PNAS), 2, 5% Proceedings of the National Academy of Sciences (PNAS) 2 publications, 5%
Frontiers Media S.A.	Frontiers Media S.A., 1, 2.5% Frontiers Media S.A. 1 publication, 2.5%
American Society for Biochemistry and Molecular Biology	American Society for Biochemistry and Molecular Biology, 1, 2.5% American Society for Biochemistry and Molecular Biology 1 publication, 2.5%
Pleiades Publishing	Pleiades Publishing, 1, 2.5% Pleiades Publishing 1 publication, 2.5%
Taylor & Francis	Taylor & Francis, 1, 2.5% Taylor & Francis 1 publication, 2.5%
OOO Zhurnal "Mendeleevskie Soobshcheniya"	OOO Zhurnal "Mendeleevskie Soobshcheniya", 1, 2.5% OOO Zhurnal "Mendeleevskie Soobshcheniya" 1 publication, 2.5%
	1 2 3 4 5 6 7 8 9

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

PDF

Metrics

Cite this

GOST |

Cite this

GOST Copy

Nath Neerukonda S., Vassell R., Weiss C. Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin // Vaccines. 2020. Vol. 8. No. 3. p. 382.

GOST all authors (up to 50) Copy

Nath Neerukonda S., Vassell R., Weiss C. Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin // Vaccines. 2020. Vol. 8. No. 3. p. 382.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.3390/vaccines8030382

UR - https://doi.org/10.3390/vaccines8030382

TI - Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin

T2 - Vaccines

AU - Nath Neerukonda, Sabari

AU - Vassell, Russell

AU - Weiss, Carol

PY - 2020

DA - 2020/07/12

PB - MDPI

SP - 382

IS - 3

VL - 8

PMID - 32664628

SN - 2076-393X

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2020_Nath Neerukonda,

author = {Sabari Nath Neerukonda and Russell Vassell and Carol Weiss},

title = {Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin},

journal = {Vaccines},

year = {2020},

volume = {8},

publisher = {MDPI},

month = {jul},

url = {https://doi.org/10.3390/vaccines8030382},

number = {3},

pages = {382},

doi = {10.3390/vaccines8030382}

}

MLA

Cite this

MLA Copy

Nath Neerukonda, Sabari, et al. “Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin.” Vaccines, vol. 8, no. 3, Jul. 2020, p. 382. https://doi.org/10.3390/vaccines8030382.

Publisher

MDPI

Journal

Vaccines

scimago Q1

wos Q2

SJR

1.024

CiteScore

9.9

Impact factor

3.4

ISSN

2076393X (Print, Electronic)